Table 1 Patient’s characteristics during follow up
Clinical presentation | Fractures | T-score lumbar/total hip BMD (SD) | Calcaemia (mmol/l) | Treatments | |
|---|---|---|---|---|---|
Follow up of the patient (January 2005) | Bicycle fall | L2 | −3.2/−2.1 | 2.50 | Initiation: denosumab (60 mg semi-annually), calcium (1 g daily), vitamin D (800 IU daily) |
FREEDOM 3-year evaluation (January 2008) | No pain | T5, T8, and aggravation of L2 | −2.2/−1.7 | 2.52 | Pursuit: denosumab (60 mg semi-annually), calcium (1 g daily), vitamin D (800 IU daily) |
FREEDOM extension (September 2013) | No pain | No new fracture | −1.6/−1.1 | 2.73 | All treatments stopped |
Hospitalization (June 2014) | Acute intense dorsal pain | T4, T9, T10, T11, L1, L3 | −2.0/−1.3 | 2.83 | None |
New evaluation (September 2016) | Chronic dorsal and lumbar pain | No new fracture | −2.9/−2.3 | 2.47 | Zoledronate (two infusions of 5 mg annually), vitamin D (100,000 IU quarterly) |
New evaluation (August 2018) | Chronic lumbar pain | No new fracture | −2.9/−2.3 | 2.60 | Treatments stopped |